Effectiveness and Safety of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligo-synovitis Resistant to Prior TNF-alpha Inhibitors

Effectiveness and Safety of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligo-synovitis Resistant to Prior TNF-alpha Inhibitors - Effectiveness and Safety of CZP in RA with Persistent Inflamed Residual Synovitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027387

Enrollment

Registered

2017-05-25

Start date

2015-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA patients with mono- or oligo-arthritis (1-5 joints) after treatment with bDMARD(s) who will be treated with CZP

Exclusion criteria

Exclusion criteria: Patients with the reasons for inadequate toparticipate in this study, due to contraindication of CZP and judeged by attending rheumatologist

Design outcomes

Primary

Measure	Time frame
Assessment of efficacy of CZP: 6 months follow-up with US	—

Secondary

Measure	Time frame
Assessment of efficacy with biomakers and side effects of CZP	—

Countries

Japan

Contacts

Public ContactSyuichi Koarada

Faculty of Medicine, Saga University Division of Rheumatology

koarada@cc.saga-u.ac.jp0952-31-6511

Outcome results